title: Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke patients.
abstract: OBJECTIVE
  We investigated plasma levels of D-dimer products of crosslinked fibrin degradation products, thrombin-antithrombin III complex, and plasmin-alpha 2-antiplasmin complex for detecting coagulation system activation in ischemic stroke patients to determine the possible effect of age on these marker levels.
  
  
  METHODS
  We measured plasma levels of these three markers in 54 acute ischemic stroke patients within 5 days of stroke onset, in 44 chronic ischemic stroke patients over 3 months from onset, and in 50 age-matched healthy subjects. We divided the stroke patients into two subgroups, those with visible occlusion and those with nonvisible occlusion having obstruction of the major cerebral artery.
  
  
  RESULTS
  The plasma levels of these three markers were significantly (p less than 0.01) higher in the stroke patients than in controls. Significant differences did not exist at any level between the patients and controls in the younger-aged subjects (less than or equal to 64 years of age), but did exist in the older-aged subjects (greater than or equal to 75 years of age). An age-related increase of the marker levels was noted between stroke patients and controls. No significant difference in the three markers was found among any of the stroke patients.
  
  
  CONCLUSIONS
  Increased levels of these markers in stroke patients seem to be related mostly to age.
authors.affiliation: Second Department of Internal Medicine, Hyogo College of Medicine, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Ono
authors.forename: T
authors.initials: T
authors.lastname: Koyama
authors.forename: A
authors.initials: A
authors.lastname: Suehiro
authors.forename: K
authors.initials: K
authors.lastname: Oku
authors.forename: K
authors.initials: K
authors.lastname: Fujikake
authors.forename: E
authors.initials: E
authors.lastname: Kakishita
mesh_terms: D000368:Aged; D000933:Antifibrinolytic Agents / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers; D001777:Blood Coagulation; D002545:Brain Ischemia / Q000097:blood*; D002561:Cerebrovascular Disorders / Q000097:blood*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis / Q000737:chemistry; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D010447:Peptide Hydrolases / Q000032:analysis; D012016:Reference Values; D000979:alpha-2-Antiplasmin
chemical_list: D000933:Antifibrinolytic Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D005341:Fibrinolysin